Levi & Korsinsky announces it has commenced an investigation of Regulus Therapeutics Inc. (“Regulus” or the “Company”) (NASDAQ: RGLS) concerning possible violations of federal securities laws.

On June 27, 2016, Regulus announced receipt of verbal notice from the U.S. Food and Drug Administration that its investigational new drug for the treatment of chronic hepatitis C infection has been placed on a clinical hold. According to Regulus, the hold was a result of a second serious adverse event of jaundice in a patient enrolled in the drug’s on-going Phase I US study. Following this news, shares of Regulus were down more than 47% on intraday trading on June 28, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/regulus-therapeutics-rgls

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLPEduard Korsinsky, Esq.Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171www.zlk.com

Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Regulus Therapeutics Charts.
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Regulus Therapeutics Charts.